# Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-egfr-mutation/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jean‐Charles Soria,Yi‐Long Wu,Kazuhiko Nakagawa,Sang-We Kim,Jin-Ji Yang,Myung‐Ju Ahn,Jie Wang,James Chih‐Hsin Yang,You Lü,Shinji Atagi,Santiago Ponce,Ki Hyeong Lee,Yunpeng Liu,Kiyotaka Yoh,Jianying Zhou,Xiaojin Shi,Alan Webster,Haiyi Jiang,Tony Mok |
| Citations | 412 |
| DOI | 10.1016/s1470-2045(15)00121-7 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2152481222 |
| PMID | 26159065 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Myung‐Ju Ahn](https://scholariq.org/researchers/myung-ju-ahn/)
- [Kiyotaka Yoh](https://scholariq.org/researchers/kiyotaka-yoh/)
- [James Chih‐Hsin Yang](https://scholariq.org/researchers/james-chih-hsin-yang/)
- [You Lü](https://scholariq.org/researchers/you-lu/)
- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.